Dianthus Therapeutics, Inc.
Dianthus Therapeutics, Inc.（DNTH）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · DNTH · 截至 2026年6月8日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
32
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Dianthus Therapeutics, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
DNTH 季度内部人买卖趋势
DNTH 内幕交易卖出 · DNTH 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · DNTH CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
DNTH 高管卖出股份 · DNTH 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Jun 1, 2026 | Randhawa Simrat EVP, Head of R&D | Option | 9,375 | $207K | Form 4 |
| Jun 1, 2026 | Randhawa Simrat EVP, Head of R&D | Sale | 5,428 | $487K | Form 4 |
| Jun 1, 2026 | Randhawa Simrat EVP, Head of R&D | Option | 6,249 | $136K | Form 4 |
| Jun 1, 2026 | Randhawa Simrat EVP, Head of R&D | Option | 6,908 | $124K | Form 4 |
| Jun 1, 2026 | Randhawa Simrat EVP, Head of R&D | Sale | 16,943 | $1.54M⚡ | Form 4 |
| Jun 1, 2026 | Randhawa Simrat EVP, Head of R&D | Option | 3,998 | $34K | Form 4 |
| Jun 1, 2026 | Randhawa Simrat EVP, Head of R&D | Sale | 4,159 | $380K | Form 4 |
| May 8, 2026 | Soteropoulos Paula Director | Option | 599 | $5K | Form 4 |
| May 8, 2026 | Soteropoulos Paula Director | Sale | 599 | $51K | Form 4 |
| Apr 9, 2026 | Savitz Ryan EVP, CFO & CBO | Option | 8,224 | $147K | Form 4 |
| Apr 9, 2026 | Savitz Ryan EVP, CFO & CBO | Sale | 8,224 | $739K | Form 4 |
| Mar 31, 2026 | Savitz Ryan EVP, CFO & CBO | Option | 40,000 | $715K | Form 4 |
| Mar 31, 2026 | Savitz Ryan EVP, CFO & CBO | Sale | 1,390 | $109K | Form 4 |
| Mar 31, 2026 | Savitz Ryan EVP, CFO & CBO | Sale | 21,825 | $1.72M⚡ | Form 4 |
| Mar 31, 2026 | Savitz Ryan EVP, CFO & CBO | Sale | 1,485 | $119K | Form 4 |
| Mar 31, 2026 | Savitz Ryan EVP, CFO & CBO | Sale | 800 | $65K | Form 4 |
| Mar 31, 2026 | Savitz Ryan EVP, CFO & CBO | Sale | 2,366 | $196K | Form 4 |
| Mar 31, 2026 | Savitz Ryan EVP, CFO & CBO | Option | 74,367 | $628K | Form 4 |
| Mar 31, 2026 | Savitz Ryan EVP, CFO & CBO | Sale | 59,800 | $5.02M⚡ | Form 4 |
| Mar 31, 2026 | Savitz Ryan EVP, CFO & CBO | Sale | 19,469 | $1.65M⚡ | Form 4 |
| Mar 31, 2026 | Savitz Ryan EVP, CFO & CBO | Sale | 7,232 | $619K | Form 4 |
| Mar 31, 2026 | Soteropoulos Paula Director | Option | 599 | $5K | Form 4 |
| Mar 31, 2026 | Soteropoulos Paula Director | Sale | 599 | $48K | Form 4 |
| Mar 24, 2026 | Soteropoulos Paula Director | Option | 27,594 | $233K | Form 4 |
| Mar 24, 2026 | Soteropoulos Paula Director | Sale | 27,594 | $2.15M⚡ | Form 4 |
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 DNTH 内幕交易
DNTH 内幕交易
Dianthus Therapeutics, Inc.（DNTH）内幕交易数据来源于公司内部人（包括Randhawa Simrat (EVP, Head of R&D), Savitz Ryan (EVP, CFO & CBO), Garcia Marino (CEO AND PRESIDENT · Director)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。DNTH内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Dianthus Therapeutics, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
DNTH 内幕交易 · 5个问题Dianthus Therapeutics, Inc.（DNTH）的内部人包括高管和董事，如Randhawa Simrat (EVP, Head of R&D), Savitz Ryan (EVP, CFO & CBO), Garcia Marino (CEO AND PRESIDENT · Director)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026